前列腺癌中的多胺代谢
Polyamine metabolism in prostate cancer.
作者信息
Sena Laura A
机构信息
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Baltimore, Maryland, USA.
出版信息
Curr Opin Oncol. 2025 May 1;37(3):223-232. doi: 10.1097/CCO.0000000000001134. Epub 2025 Feb 20.
PURPOSE OF REVIEW
Normal and malignant prostate engage in high rates of de novo polyamine synthesis. This review considers how polyamine metabolism regulates prostate cancer initiation and progression.
RECENT FINDINGS
The androgen receptor (AR) establishes a metabolic program to drive robust polyamine synthesis in the normal prostate. Upon malignant transformation, this AR-driven metabolic program persists and is optimized for oncogenesis by the proto-oncogene MYC and/or alterations to PI3K signaling. A deeper understanding of the function of polyamines in prostate cancer may be obtained by considering their function in the normal prostate.
SUMMARY
Recent findings support ongoing research into the role of polyamines in driving prostate cancer initiation and progression and suggest targeting polyamine metabolism remains a promising therapeutic strategy for prevention and treatment of prostate cancer.
综述目的
正常前列腺组织和恶性前列腺肿瘤均具有较高的多胺从头合成速率。本综述探讨多胺代谢如何调节前列腺癌的发生和发展。
最新发现
雄激素受体（AR）建立了一种代谢程序，以驱动正常前列腺组织中旺盛的多胺合成。发生恶性转化后，这种由AR驱动的代谢程序持续存在，并通过原癌基因MYC和/或PI3K信号通路的改变，针对肿瘤发生进行了优化。通过考虑多胺在正常前列腺组织中的功能，可能会更深入地了解其在前列腺癌中的作用。
总结
最新发现支持了对多胺在前列腺癌发生和发展中作用的持续研究，并表明靶向多胺代谢仍然是预防和治疗前列腺癌的一种有前景的治疗策略。
Zotero 插件